Superworth

Eledon Pharmaceuticals revenue ELDN

Sales by quarter and over the last twelve months, from 2013.

Last 12 months, to Mar 31, 2017
$0
Latest quarter, Q1 FY17
$0
Fiscal year 2016
$0

Eledon Pharmaceuticals' revenue was $0 over the twelve months to Mar 31, 2017.

In its latest quarter, Q1 FY17, it was $0.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2016$0n/a
FY2015$0n/a
FY2014$0n/a
FY2013$0n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q1 FY17$0n/a$0
Q4 FY16$0n/a$0
Q3 FY16$0n/a$0
Q2 FY16$0n/a$0
Q1 FY16$0n/a$0
Q4 FY15$0n/a$0
Q3 FY15$0n/a$0
Q2 FY15$0n/a$0
Q1 FY15$0n/a$0
Q4 FY14$0n/a$0
Q3 FY14$0n/a$0
Q2 FY14$0n/a$0

Against its peers

Companies in Drug Manufacturers - General nearest Eledon Pharmaceuticals' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
ELDNEledon Pharmaceuticalsn/m
NATRNatures Sunshine Products$492M+7% a year
LFVNLifevantage$182.6M−20% a year
ARVNArvinas$316.7M−15% a year
SPROSpero Therapeutics$47M−3% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
ATNMActinium Pharmaceuticalsn/m
COLLCollegium Pharmaceutical$808.2M+14% a year
Peer median$316.7M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Eledon Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.